Citations

Clear

3485 citation(s) found for "Sy, Sarah".

SAFETY AND EFFICACY OF THE PD‐L1 INHIBITOR DURVALUMAB WITH R‐CHOP OR R2‐CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH‐RISK DLBCL
Nowakowski, Grzegorz S. , Willenbacher, Wolfgang , Greil, Richard , Larsen, Thomas Stauffer , Manges, Robert, Trümper, Lorenz, Everaus, Hele, Kalakonda, Nagesh , Knoble, Jeanna, Jørgensen, Judit , Rubio, Neus Domper, Casadebaig, Marie‐Laure, Manzke, Oliver, Cunningham, David , Patel, Krish , Jäger, Ulrich , Haïoun, Corinne , Brown, Peter de Nully , Cunningham, David , Muñoz, Javier

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 132-134

10.1002/hon.93_2629 Get It

Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high‐risk follicular lymphoma: CALGB 50904 (Alliance)
Blum, Kristie A. , Polley, Mei‐Yin C. , Dockter, Travis , Anderson, Sarah , Wagner‐Johnston, Nina D. , Christian, Beth , Atkins, Jim, Cheson, Bruce D. , Leonard, John P. , Bartlett, Nancy L. , Polley, Mei-Yin, Dockter, Travis J, Bartlett, Nancy L , Jung, Sin‐Ho , Hsi, Eric D.

Mayo Clinic

Cancer | June 7, 2019 | Volume: 125 | Issue: 19 | Pages: 3378-3389

10.1002/cncr.32289 | PMID 31174236 Get It

BackgroundThis multicenter, randomized phase 2 trial evaluated complete responses (CRs), efficacy, and safety with ofatumumab and bendamustine and with ofatumumab, bendamustine, and bortezomib in patients with untreated, high‐risk follicular lymphoma (FL).MethodsPatients with grade 1 to 3a FL and either a Follicular Lymphoma International Prognostic Index (FLIPI) score of 2 with 1 lymph node >6 cm or an FLIPI score of 3 to 5 were randomized to arm A (ofatumumab, bendamustine, and maintenance ofatumumab) or to arm B (ofatumumab, bendamustine, bortezomib, and maintenance ofatumumab and bortezomib).ResultsOne hundred twenty‐eight patients (66 in arm A and 62 in arm B) received treatment. The median age was 61 years, and 61% had disease >6 cm; 29% had an FLIPI score of 2, and 71% had an FLIPI score of 3 to 5. In arm A, 86% completed induction, and 64% completed maintenance. In arm B, 66% and 52% completed induction and maintenance, respectively. Dose modifications were required in 65% and 89% in arms A and B, respectively. Clinically significant grade 3 to 4 toxicities included neutropenia (A, 36%; B, 31%), nausea/vomiting (A, 0%; B, 8%), diarrhea (A, 5%; B, 11%), and sensory neuropathy (A, 0%; B, 5%). The estimated CR rates were 62% (95% confidence interval [CI], 50%‐74%) and 60% (95% CI, 47%‐72%) in arms A and B, respectively (P = .68). With a median follow‐up of 3.3 years, the estimated 2‐year progression‐free survival (PFS) and overall survival (OS) rates were 80% and 97%, respectively, for arm A and 76% and 91%, respectively, for arm B.ConclusionsThe CR rates, PFS, and OS were not improved with the addition of bortezomib to ofatumumab and bendamustine in patients with high‐risk FL. Although grade 3 to 4 toxicities were similar, more patients treated with bortezomib required dose modifications and early discontinuation.
Increased local failure for patients with intermediate‐risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group
Casey, Dana L. , Donaldson, Sarah S. , Hawkins, Douglas S. , Tian, Jing , Arndt, Carola A.S., Rodeberg, David A. , Gupta, Abha A. , Yock, Torunn I. , Hawkins, Douglas S , Arndt, Carola A., Gupta, Abha A , Donaldson, Sarah S , Casey, Dana L , Chi, Yueh‐Yun , Routh, Jonathan C. , Lautz, Timothy B. , Wolden, Suzanne L.

Mayo Clinic

Cancer | June 7, 2019 | Volume: 125 | Issue: 18 | Pages: 3242-3248

10.1002/cncr.32204 | PMID 31174239 Get It

Background The objective of this study was to evaluate local control for patients with intermediate‐risk rhabdomyosarcoma (RMS) treated on Children's Oncology Group (COG) protocol ARST0531. Methods This study analyzed 424 patients with intermediate‐risk RMS. Patients were randomized to chemotherapy with either vincristine, dactinomycin, and cyclophosphamide (VAC) or VAC alternating with vincristine and irinotecan. With the goal of improving local control, radiation therapy (RT) was delivered early at week 4 and was concurrent with irinotecan in the experimental arm. Individualized local control plans for children 24 months old or younger were allowed. Local failure on ARST0531 was compared with local failure on the preceding COG intermediate‐risk study, D9803. Results For patients with group I/II alveolar RMS (n = 55), the 5‐year cumulative incidence of local failure was 13.4%; for group III alveolar RMS (n = 141), it was 20.2%; and for group III embryonal RMS (n = 228), it was 27.9% ( P = .03). Among patients with group III disease, local failure did not differ by histology, site, nodal status, RT modality, or treatment arm. Local failure was worse for a tumor size >5 cm (32.3% vs 16.7%; P = .001). Among patients with group III embryonal RMS, local failure was higher on ARST0531 than D9803 (27.9% vs 19.4%; P = .03). After the exclusion of patients 24 months old or younger or patients who did not receive radiation, local failure remained significantly increased on ARST0531 ( P = .02). After adjustments for clinical prognostic factors, event‐free survival and overall survival were worse on ARST0531 ( P = .004 and P = .05, respectively). Conclusions Despite interventions designed to enhance local control, local control was inferior on ARST0531 in comparison with D9803. The reason for this is unclear, but it could be the reduced cyclophosphamide dose on ARST0531.
Long‐term outcomes of the octogenarian donor liver recipient: The era of the new centurion
Schneider, Sarah , Jaime, Francia Díaz , Mara, Kristin C. , Dierkhising, Ross , Watt, Kymberly D. , Berenguer, Marina , Díaz Jaime, Francia , Mara, Kristin, Berenguer, Marina , Mara, Kristin C , Schneider, Sarah, Heimbach, Julie K.

Mayo Clinic

Clinical Transplantation | June 7, 2019 | Volume: 33 | Issue: 8 | Pages: No page available

10.1111/ctr.13629 | PMID 31173653 Get It

AbstractBackgroundStudies have suggested transplantation using older donor livers results in similar short‐term outcomes as younger donor livers; however, little data exist on long‐term patient/graft outcomes of the octogenarian liver recipient.MethodsRetrospective data were collected from 2 centers, (Valencia, Spain and Rochester, MN, USA) of all recipients of octogenarian donor liver allografts from 2000 to 2011 with follow‐up to 2016. The aim was to compare long‐term patient/graft survival as well as metabolic outcomes of the recipient with the octogenarian liver vs younger than 60 years donor.Results78 recipients of older liver allografts were compared to 78 matched controls. No difference in 10‐year patient mortality was demonstrated (P = 0.074). Octogenarian livers were associated with 3‐fold higher likelihood of graft failure (P = 0.002) but no increase in the risk of post‐LT cardiovascular disease (P = 0.60), hypertension (P = 0.33), vascular complications (P = 0.53), or malignancy (P = 0.14). In multivariate analysis, elder livers remained a significant factor associated with rejection (P = 0.034) with a trend not reaching statistical significance for graft failure (P = 0.052).ConclusionsFor appropriately selected recipients, receiving an octogenarian liver does not clearly influence patient survival but does impact early graft survival with a notable increase in early posttransplant rejection rates and re‐transplantation. Over 1.5 decades, older allografts have not adversely affected metabolic outcomes.
Barriers to accrual and enrollment in brain tumor trials
Lee, Eudocia Q. , Chukwueke, Ugonma , Hervey‐Jumper, Shawn L. , Leone, José Pablo , Chang, Susan M. , Arons, David, Oliver, Kathy , Verble, Kay, Musella, Al , Willmarth, Nicole E. , Doherty, Lisa, Gaffey, Sarah, Halkin, Thomas, Friday, Bret Edward Buckley, Fouladi, Maryam , Macdonald, David R., Peñas-Prado, Marta , Vogelbaum, Michael A. , Sahebjam, Solmaz , Sandak, David, Bent, Martin J. van den , Weller, Michael , Reardon, David A. , Wen, Patrick Y. , Galanis, Evanthia , Weller, Michael , van den Bent, Martin J , Groot, John de , Armstrong, Terri S. , Chang, Susan Marina , Alexander, Brian M. , Bates, Amanda, Lin, Nancy U. , Mehta, Minesh P. , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | June 7, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/neuonc/noz104 | PMID 31175826 Get It

Abstract Many factors contribute to the poor survival of malignant brain tumor patients, some of which are not easily remedied. However, one contributor to the lack of progress that may be modifiable is poor clinical trial accrual. Surveys of brain tumor patients and neuro-oncology providers suggest that clinicians do a poor job of discussing clinical trials with patients and referring patients for clinical trials. Yet, data from the Cancer Action Network of the American Cancer Society suggest that most eligible oncology patients asked to enroll on a clinical trial will agree to do so. To this end, the Society for Neuro-Oncology (SNO) in collaboration with the Response Assessment in Neuro-Oncology (RANO) Working Group, patient advocacy groups, clinical trial cooperative groups, including the Adult Brain Tumor Consortium (ABTC), and other partners are working together with the intent to double clinical trial accrual over the next 5 years. Here we describe the factors contributing to poor clinical trial accrual in neuro-oncology and offer possible solutions.
Comparison of 99mTc-Sestamibi Molecular Breast Imaging and Breast MRI in Patients With Invasive Breast Cancer Receiving Neoadjuvant Chemotherapy
Hunt, Katie N. , Conners, Amy Lynn , O’Connor, Michael K. , Weinshilboum, Richard, Wang, Liewei , Carter, Jodi M. , McLaughlin, Sarah A. , Aspitia, Alvaro Moreno, Gray, Richard J. , Northfelt, Don W., O'Connor, Michael K, Suman, Vera, Kalari, Krishna, Carter, Jodi, Northfelt, Don, Goetz, Matthew P. , Suman, Vera J. , Kalari, Krishna R. , Boughey, Judy C. , Carter, Jodi

Mayo Clinic

American Journal of Roentgenology | June 5, 2019 | Volume: 213 | Issue: 4 | Pages: 932-943

10.2214/ajr.18.20628 | PMID 31166752 Get It

Outcomes in patients with DNA-damage repair related pancreatic cancer
Macklin, Sarah , Hines, Stephanie L., Kasi, Pashtoon Murtaza , Kasi, Pashtoon Murtaza

Mayo Clinic

No container title available | June 3, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.2.10012/v1 Get It

Abstract Background: Patients with DNA-damage response genes (DDR)-related pancreas cancer (BRCA1/2 or other DNA-damage related genes) may have improved outcomes secondary to increased sensitivity to DNA-damaging drugs (platinum chemotherapy/ poly ADP ribose polymerase (PARP)-inhibitors). However, data is scarce pertaining to outcomes in this subset of patients. Our objective was to retrospectively identify DDR-related pancreas cancer patients and report on clinical outcomes. Methods: Pancreas cancer patients with either a somatic or germline BRCA1/2 or other DDR genes were identified retrospectively through review of medical records (medical genetics/oncology), germline and tumor-based genetic testing results at our institution. Data regarding clinical outcomes, therapy received, and survival was subsequently extracted. Results: A total of 11 patients with pancreas cancer were identified. Pathogenic DDR-variants detected were within BRCA1 (3), ATM (4), BRCA2 (2), PALB2 (1) and FANCC (1). Five of these individuals had prior history of other cancers. Clinically these tumors were localized (4), locally advanced (3), and metastatic (4) at diagnosis. Seven out of 11 patients were still alive at time of data review. Survival in the 3 patients who had died in the metastatic/advanced cohort was 23.5, 25.8 and 111.5 months. All patients with advanced disease had exposure to platinum chemotherapy. Conclusions: Historical survival in patients with advanced and metastatic pancreas cancer is poor. Results of this DDR-subset of patients do show significantly superior outcomes, likely secondary to exposure to platinum drugs. This data, alongside other similar cohorts, would favor the DDR-genes being a predictive marker with improved survival if exposed to these drugs and the new class of drugs, PARP-inhibitors.
Postmastectomy Radiation Therapy (PMRT) before and after 2-Stage Expander-Implant Breast Reconstruction: A Systematic Review
Oliver, Jeremie D. , Huayllani, María T. , Restrepo, David J. , Sisti, Andrea , Manrique, Oscar J. , Broer, P. Niclas, McLaughlin, Sarah A. , Rinker, Brian, Forte, Antonio J. , Boczar, Daniel , Huayllani, Maria T , Sisti, Andrea , Rinker, Brian D, Forte, Antonio Jorge , Oliver, Jeremie D

Mayo Clinic

Medicina | May 30, 2019 | Volume: 55 | Issue: 6 | Pages: 226

10.3390/medicina55060226 | PMID 31146506 Get It

Background: In those undergoing treatment for breast cancer, evidence has demonstrated a significant improvement in survival, and a reduction in the risk of local recurrence in patients who undergo postmastectomy radiation therapy (PMRT). There is uncertainty about the optimal timing of PMRT, whether it should be before or after tissue expander or permanent implant placement. This study aimed to summarize the data reported in the literature on the effect of the timing of PMRT, both preceding and following 2-stage expander-implant breast reconstruction (IBR), and to statistically analyze the impact of timing on infection rates and the need for explantation. Methods: A comprehensive systematic review of the literature was conducted using the PubMed/Medline, Ovid, and Cochrane databases without timeframe limitations. Articles included in the analysis were those reporting outcomes data of PMRT in IBR published from 2009 to 2017. Chi-square statistical analysis was performed to compare infection and explantation rates between the two subgroups at p < 0.05. Results: A total of 11 studies met the inclusion criteria for this study. These studies reported outcomes data for 1565 total 2-stage expander-IBR procedures, where PMRT was used (1145 before, and 420 after, implant placement). There was a statistically significant higher likelihood of infection following pre-implant placement PMRT (21.03%, p = 0.000079), compared to PMRT after implant placement (9.69%). There was no difference in the rate of explantation between pre-implant placement PMRT (12.93%) and postimplant placement PMRT (11.43%). Conclusion: This study suggests that patients receiving PMRT before implant placement in 2-stage expander–implant based reconstruction may have a higher risk of developing an infection.
Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease
Liu, Huan , He, Jin , Koh, Su Pin , Zhong, Yuping , Liu, Zhiqiang , Wang, Zhi‐Qiang , Zhang, Yujin , Li, Zongwei , Tam, Bjorn T. , Xiao, Min , Starbuck, Michael W., Navone, Nora M. , Davis, R. Eric , Tong, Qiang , Bergsagel, P. Leif , Yi, Qing , Orlowski, Robert Z. , Yang, Jing , Bergsagel, P. Leif , Xiao, Min , Amini, Behrang , Navone, Nora M , Davis, Richard E , Tong, Qiang , Yi, Qing , Gagel, Robert F. , Yang, Jing , Orlowski, Robert Z. , Lin, Pei , Young, Ken H. , Lee, Hans C. , Hou, Jian , Liu, Zhiqiang

Mayo Clinic

Science Translational Medicine | May 29, 2019 | Volume: 11 | Issue: 494 | Pages: No page available

10.1126/scitranslmed.aau9087 | PMID 31142679 Get It

Marrow adipocytes reprogrammed by myeloma cells induce bone lesions.
Functional control of electrophysiological network architecture using direct neurostimulation in humans
Khambhati, Ankit N. , Costantini, Julia , Ezzyat, Youssef , Solomon, Ethan A. , Jobst, Barbara C. , Sheth, Sameer A. , Seger, Sarah , Weiss, Shennan A. , Sperling, Michael R. , Gorniak, Richard , Rizzuto, Daniel S. , Kahana, Michael J. , Lucas, Timothy H., Bassett, Danielle S. , Sperling, Michael R , Weiss, Shennan A , Kahn, Ari E. , Gross, Robert E. , Zaghloul, Kareem A. , Worrell, Gregory A. , Lega, Bradley Charles , Das, Sandhitsu R. , Stein, Joel M. , Davis, Kathryn A. , Tracy, Joseph I. , Jobst, Barbara

Mayo Clinic

Network Neuroscience | May 28, 2019 | Volume: 3 | Issue: 3 | Pages: 848-877

10.1162/netn_a_00089 | PMID 31410383 Get It

Chronically implantable neurostimulation devices are becoming a clinically viable option for treating patients with neurological disease and psychiatric disorders. Neurostimulation offers the ability to probe and manipulate distributed networks of interacting brain areas in dysfunctional circuits. Here, we use tools from network control theory to examine the dynamic reconfiguration of functionally interacting neuronal ensembles during targeted neurostimulation of cortical and subcortical brain structures. By integrating multimodal intracranial recordings and diffusion-weighted imaging from patients with drug-resistant epilepsy, we test hypothesized structural and functional rules that predict altered patterns of synchronized local field potentials. We demonstrate the ability to predictably reconfigure functional interactions depending on stimulation strength and location. Stimulation of areas with structurally weak connections largely modulates the functional hubness of downstream areas and concurrently propels the brain towards more difficult-to-reach dynamical states. By using focal perturbations to bridge large-scale structure, function, and markers of behavior, our findings suggest that stimulation may be tuned to influence different scales of network interactions driving cognition.